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Background:Chronic lymphocytic inflammation with
pontine perivascular enhancement responsive to ste-
roids (CLIPPERS) is a central nervous system inflamma-
tory disease.
Objective:To describe the disease course of CLIPPERS.
Design: A nationwide study was implemented to col-
lect clinical, magnetic resonance imaging, cerebrospi-
nal fluid, and brain biopsy specimen characteristics of
patients with CLIPPERS.
Setting: Academic research.
Patients: Twelve patients with CLIPPERS.
Main Outcome Measures: The therapeutic manage-
ment of CLIPPERS was evaluated.
Results: Among 12 patients, 42 relapses were ana-
lyzed. Relapses lasted a mean duration of 2.5 months,
manifested frequent cerebellar ataxia and diplopia, and
were associated with a mean Expanded Disability Status
Scale (EDSS) score of 4. Besides typical findings of
CLIPPERS, magnetic resonance imaging showed brain-
stemmass effect in 5 patients, extensive myelitis in 3 pa-
tients, and closed ring enhancement in 1 patient. Incon-
stant oligoclonal bandswere found on cerebrospinal fluid
investigation in 4 patients, with an increased T-cell ra-
tio of CD4 to CD8. Among 7 available brain biopsy speci-
mens, staining was positive for perivascular CD4 T lym-
phocytes in 5 samples. Thirty-eight of 42 relapses were
treated with pulse corticosteroid therapy, which led to
improvement, with a mean residual EDSS score of 1.9
(range, 0-7). In 1 patient with untreated relapses, scores
on the EDSS progressively increased to a score of 10 at
death. Among 5 patients without long-term corticoste-
roid therapy, the mean annualized relapse rate was 0.5
(range, 0.25-2.8). Among 7 patients taking oral cortico-
steroids, no relapses occurred in those whose daily dose
was 20mg or higher. No progressive course of CLIPPERS
was observed. Four patients with a final EDSS score of 4
or higher had experienced previous severe relapses (EDSS
score, 5) and brainstem and spinal cord atrophy.
Conclusions: CLIPPERS is a relapsing-remitting disor-
derwithout progressive forms. Long-termdisability is cor-
relatedwith the severity of previous relapses. Further stud-
ies are needed to confirm that prolonged corticosteroid
therapy prevents further relapses.
Arch Neurol. 2012;69(7):847-855
C HRONIC LYMPHOCYTICinflammation with pon-tine perivascular enhance-ment responsive to ste-roids (CLIPPERS) is a
central nervous system (CNS) inflamma-
tory disease defined in 2010 by Pittock and
colleagues.1 They described 8 patientswith
common clinical, radiological, and
pathological features of brainstem involve-
ment that was responsive to and depen-
dent on corticosteroid therapy. The diag-
nostic criteria for CLIPPERS include the
following: (1) episodic brainstem symp-
toms, (2) characteristic punctuate and cur-
vilinear gadolinium-enhancing lesions
peppering the brainstem (mainly in the
pons) on magnetic resonance (MR)
imaging, and (3) T-lymphocytic infiltrate
with perivascular predominance in brain
biopsy specimens. Pittock et al1 suggested
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that CLIPPERS diagnosis could be made without brain
biopsy if clinical and MR imaging features of the disease
were present and if alternative diagnoses were ex-
cluded. Since then, 15 additional cases of CLIPPERS have
been reported.2-10
Wedescribe 12 patientswithCLIPPERSwhowere con-
secutively identified through anationwide study. The aims
of the present study were to further analyze the clinical
features, disease course, MR imaging, cerebrospinal fluid
(CSF) findings, and brain biopsy specimen characteris-
tics of patients with CLIPPERS and to propose a thera-
peutic management.
METHODS
The study inclusion criteria were the following: (1) recur-
rence of brainstem symptoms, (2) punctuate and curvilinear
gadolinium-enhancing lesions involving the pons ormiddle cer-
ebellar peduncle on MR imaging, (3) clinical and radiological
response to corticosteroids, and (4) no evidence of alternative
CNS disease. A brain biopsy specimen was obtained if clinical
or MR imaging criteria were not fulfilled. Twelve patients from
9 university multiple sclerosis centers were included to assess
multiple sclerosis diagnosis. Early in the disease course, mul-
tiple sclerosis diagnosis was clearly excluded in all 12 pa-
tients. For each patient, datawere retrospectively analyzed since
the onset of their disease. Two of 12 patients included herein
were previously described.2,9
CLINICAL EVALUATIONS
The following patient characteristics were collected: sex, age
at onset, and personal and family history of autoimmune dis-
ease. Neurological and systemic signs during relapses and re-
lapse duration and severity using the Expanded Disability Sta-
tus Scale (EDSS) were analyzed. Based on patients’ EDSS scores
after the treatment of relapses, their disease was categorized as
resistant to corticosteroids (when the EDSS score was un-
changed) or as responsive to corticosteroids (when the EDSS
score stabilized or improved). Patients’ EDSS scores were ob-
tained at the following time points: during relapses, between
relapse-free periods (residual EDSS score), and at the end of
the follow-up period (last EDSS score). Fatigue, weight loss
(10% of the initial body weight), and depression (according
toDiagnostic and Statistical Manual of Mental Disorders [Fourth
Edition] criteria) were considered possible systemic features.
Acute treatment included high doses of corticosteroids (oral
or intravenous). When corticosteroid treatment was contin-
ued for more than 2 months, it was considered long-term cor-
ticosteroid therapy. Patients were categorized as not receiving
long-term corticosteroid therapy or as receiving long-term cor-
ticosteroid therapy.
LABORATORY TESTS
All patients underwent laboratory screening that included com-
plete blood cell count, renal and liver function, creatine ki-
nase and low-density lipoprotein cholesterol levels, C-
reactive protein level, erythrocyte sedimentation rate, serum
protein electrophoresis, immunofixation, thyroid hormone lev-
els, and urinalysis. Autoimmune serological evaluations in-
cluded antinuclear and anti–extractable nuclear antigen anti-
bodies, rheumatoid factor, complement levels, cryoglobulinemia,
antineutrophil cytoplasmic antibodies, lupus anticoagulant, anti–
2-glycoprotein 1 and anticardiolipin antibodies, angiotensin-
converting enzyme, anti–aquaporin 4 antibody, thyroid auto-
antibodies, and onconeuronal antibodies (anti-Yo, anti-Hu, anti-
Ri, anti-Tr, anti-Ma2, antiamphiphysin, and anti-CV2
antibodies). Five patients were screened for anti-GQ1b anti-
body.Virological andbacteriological examination includedhepa-
titis C virus, hepatitis B virus, human immunodeficiency vi-
rus, VDRL test, and Treponema pallidum hemagglutination, and
Borrelia burgdorferi serological evaluations were systemati-
cally performed. Results for all these laboratory tests were nor-
mal or negative. All patients underwent CSF analysis, includ-
ing immunoelectrophoresis. Cerebrospinal fluid lymphocyte
phenotyping was performed in 4 patients.
IMAGING
Brain MR imaging (1.5 T) was performed, including T1-
weighted, T2-weighted, fluid-attenuated inversion recovery, T2-
weighted gradient-echo images, and diffusion-weighted im-
ages, as well as apparent diffusion coefficient, time-of-flightMR
angiography, and gadolinium-enhanced T1-weighted imaging.
All patients underwent at least 1 spinal cord MR imaging ses-
sion, including gadolinium-enhancedT1-weighted imaging. Lo-
calization, size, gadolinium enhancement, and mass effect of
the lesions were analyzed during relapses. Based on changes
in the size or number of lesions after the treatment of relapses
(using T2-weighted and gadolinium-enhanced T1-weighted se-
quences), lesions were categorized as resistant to corticoste-
roids (when lesions were unchanged) or as responsive to cor-
ticosteroids (when the size or number of lesions decreased or
gadolinium enhancement decreased or disappeared). At the end
of the follow-up period, the presence of atrophy, black holes,
and cystic cavities was assessed. Thoracoabdominopelvic com-
puted tomography and whole-body positron emission tomog-
raphy with 18fluorodeoxyglucose were performed in all pa-
tients, and these findings were normal.
PATHOLOGICAL INVESTIGATIONS
In 7 patients, cerebral biopsy specimens were obtained. His-
tological sections were stained with hematoxylin-eosin, with
Bielschowsky stain, and for the following antigens: CD3, CD20,
CD68, CD38, CD138, CD1a, -amyloid, neurofilament, and
glial fibrillary acid protein. In 5 patients, histological sections
were also stained for CD4, CD8, and granzyme B.
RESULTS
SYMPTOMS AND CLINICAL SIGNS
DURING RELAPSES
Twelve patients (9 men and 3 women) of white race/
ethnicity met the diagnostic criteria for inclusion in the
study. Their clinical features are summarized in the Table.
The mean age at the onset of symptoms was 46.5 years
(age range, 13-64 years). After a mean follow-up period
of 5.5 years (range, 0.5-34 years), 42 relapses (mean, 0.63
annual relapses per patient) had occurred. Relapses con-
sisted of isolated brainstem signs (33 relapses), brain-
stem and spinal cord signs (8 relapses), and isolated spi-
nal cord signs (1 relapse). Cerebellar ataxia (in 31
relapses), diplopia (in 16 relapses), and gaze-evoked nys-
tagmus (in 13 relapses) were the most frequent symp-
toms during relapses. At the end of the follow-up pe-
riod, all patients had experienced at least 1 relapse with
brainstem signs, and 4 of 12 patients had experienced at
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least 1 relapse with spinal cord signs. Cortical or extra-
pyramidal symptoms were not observed. Clinical char-
acteristics of individual patients during relapses are sum-
marized in Figure 1.
DURATION, SEVERITY, AND RESPONSE
TO CORTICOSTEROID TREATMENT
DURING RELAPSES
Of 42 relapses, 38 relapses were treated with high doses
of corticosteroids (intravenous methylprednisolone ac-
etate in 29 relapses and oral prednisone in 9 relapses).
Four relapses (in 3 patients) were not treated, with vari-
able evolution that included recovery without sequelae
(patient 5), recovery with sequelae (patient 4), no re-
covery (patient 4), and worsening to an EDSS score of
10 at death (patient 3).
During relapses, the mean time between the onset of
symptoms and themaximumEDSS scorewas 2.5months
(range, 0.25-18 months). The mean EDSS score during
relapses was 4 (range, 3-10), and themean residual EDSS
score after relapses was 1.9 (range, 0-7). In 38 relapses
treatedwith corticosteroids, progressive EDSS scorewors-
eningwas seen until pulse corticosteroid therapywas ini-
tiated (Figure 1). During 2 relapses in patient 6, very high
corticosteroid doses (intravenousmethylprednisolone [1
g once daily] for 6 days and 10 days, respectively) were
needed to obtain clinical improvement. For all relapses,
corticosteroid treatment was successful. Clinical im-
provement was observed within 2 weeks following the
start of corticosteroid therapy and had a similar course
in intravenously and orally treated patients.
At the end of the follow-up period, the mean EDSS
score was 3.8 (range, 0-10), with only one asymptom-
atic patient (patient 11, with an EDSS score of 0). These
results are summarized in Figure 2 and Figure 3.
LONG-TERM CORTICOSTEROID THERAPY
Patients 1 through 5 did not receive long-term corticoste-
roid therapy, andpatients6 through12received long-term
corticosteroid therapy. The follow-up results in patients 1
through5suggestthenaturalhistoryofthisdisease(Figure2).
Themeanannualizedrelapseratewas0.5(range,0.25-2.8).
In patients receiving long-term corticosteroid therapy,
no relapse occurred when the daily dose was 20 mg or
higher. As seen in patient 11 and patient 12, relapse-
free periodswere longerwhen corticosteroidweaningwas
slower (Figure 3).
Comparisonwas difficult because of a difference in the
mean follow-upperiodbetweenpatientsnot receiving long-
term corticosteroid therapy (130 months; range, 16-408
months) vs patients receiving long-term corticosteroid
therapy (20months; range, 6-53months). Severe relapses
(defined as an EDSS score of 5) were more frequent in
patients not receiving long-termcorticosteroid therapy (se-
vere relapse occurred in 3 patients) than in patients receiv-
ing long-term corticosteroid therapy (severe relapse oc-
curred in 1 patient), and long-term evolution was more
severe in patients not receiving long-term corticosteroid
Table. Clinical Features of 12 Patients Having Chronic Lymphocytic Inflammation With Pontine Perivascular Enhancement
Responsive to Corticosteroids
Patient No./
Sex/Age
at Onset, y
Follow-up
Period,
mo
Symptoms Other
Than Brainstem
Involvement
During Relapses
Gadolinium-Enhancing
Lesions Other Than
Brainstem or Cerebellar
Areas, Juxtacortical
Lesions, Brainstem
Swelling, Atrophy,
or Black Hole
Presence
of Oligoclonal
Bands
Brain
Biopsy
Immunosuppressive
Therapy
Relapses
Last
EDSS
Score
Total
No.
No. With EDSS
Score5
Not Receiving Long-term Corticosteroid Therapy
1/M/52 16 No Brainstem swelling No Yes No 2 0 2.5
2/M/39 24 No Supratentorial area No No No 6 0 2
3/M/64 21 Psychomotor
slowing
Supratentorial area,
juxtacortical lesions
Yes Yes No 3 1 10
4/M/46 182 Paraparesis,
neurogenic
bladder
Supratentorial area,
spinal cord,
juxtacortical lesions,
spinal cord atrophy
Yes Yes Cyclophosphamide 4 2 6.5
5/M/13 408 Psychomotor
slowing,
tetraparesis
Supratentorial area,
spinal cord,
brainstem swelling,
brainstem atrophy
Yes Yes Rituximab 12 1 7
Receiving Long-term Corticosteroid Therapy
6/M/58 10 Psychomotor
slowing
Supratentorial area,
juxtacortical lesions
No Yes No 1 1 4.5
7/F/48 6 No Brainstem swelling No Yes No 2 0 2.5
8/M/32 16 Hemiparesis,
sensory loss
Supratentorial area,
spinal cord,
brainstem swelling,
black hole
No No No 2 0 3
9/F/46 8 No Brainstem swelling Yes Yes No 2 0 2
10/M/46 16 Tetraparesis Spinal cord No No No 2 0 2.5
11/M/62 27 No Supratentorial area No No No 3 0 0
12/F/53 53 No Supratentorial area,
juxtacortical lesions
No No Cyclophosphamide 3 0 2.5
Abbreviation: EDSS, Expanded Disability Status Scale.
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therapy (3 patients had a last EDSS score of6.5) than in
patients receiving long-term corticosteroid therapy (1 pa-
tient had a last EDSS score of 4.5).
Relapsing-remitting evolution was constant in all 12
patients. No progressive form was observed.
MONOCLONAL ANTIBODY AND
IMMUNOSUPPRESSIVE MEDICATIONS
Three of 12 patients received additional immunosuppres-
sive drugs. These included 1 cycle of anti-CD20monoclo-
nal antibody (intravenous rituximab [375 mg/m] twice
weekly for 4weeks) (in patient 5) and 6 intravenous cycles
of cyclophosphamide (1 g monthly for 6 months) (in pa-
tient 4 and patient 12). Among these 3 patients (patients
4, 5, and 8), only patient 4 experienced a relapse 1 month
after immunosuppressive treatment.
NEUROIMAGING
Amean of 7 (range, 4-16) brainMR imaging sessions per
patient was performed. Each patient underwent MR
imaging during and after each relapse.
Distributions of lesions seen onT2-weighted and gado-
linium-enhanced T1-weighted images during relapses are
shown in eFigure 1 (http://www.archneurol.com). Dur-
ing relapses,MR imaging revealed brainstem involvement
in all patients and showedcharacteristic punctuate and cur-
vilinear gadolinium enhancement in the pons or middle
cerebellar peduncle (eFigure 2). In most cases, the gado-
linium-enhancing lesions decreased in number as the dis-
tance from the pons increased. They predominantly in-
volved pontocerebellar and corticospinal tracts. These
abnormalities were seen from the first relapse in all pa-
tients except patient 5, in whom typical MR imaging fea-
tures of CLIPPERS were observed at 9 years after the on-
set of disease (during a 12th relapse).2 The mean size of
the gadolinium-enhancing lesions was 1 to 3 mm (eFig-
ure 1); few lesions exceeded 3 mm. Gadolinium-
enhancing lesions exceeding 3 mm had a typical nodular
aspect (Figure 4A). Only one lesion with closed ring en-
hancement was observed (Figure 4B). Increased T2-
weighted signal was present in the corresponding gado-
linium-enhancing lesions but often exceeded 3 mm, with
a tendency to confluence (Figure 4C and D). Lesions af-
fected whitematter (ie, corticospinal tract and corpus cal-
losum) and gray matter (ie, dentate nucleus, basal gan-
glia, and hippocampus), although cortical and cerebellar
cortex and red nucleus were spared. Cerebellar, supraten-
torial, and spinal cord involvement were seen in 10 pa-
tients, 8 patients, and 4 patients, respectively. Juxtacorti-
cal (but not cortical) lesions were seen in 4 patients
(Figure 4E and F). Spinal cord involvement was variable,
ranging from small punctuate lesions at 1 vertebral level
(patient 10) to large confluent lesions involving a maxi-
mumof 3 vertebral levels (patients 4, 5, and 8) (Figure 4G
and H). Pons or middle cerebellar peduncle swelling was
seen in 5 patients (Figure 4I).
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Figure 1. Clinical characteristics of patients during relapses. A, Duration of relapses, with corresponding Expanded Disability Status Scale (EDSS) scores. Treated
relapses are indicated by diamonds and untreated relapses by squares. B, Individual patient clinical characteristics during the cumulative relapses.
INO indicates internuclear ophthalmoplegia.
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Using gadolinium-enhanced T1-weighted imaging, re-
sponse to corticosteroid therapy was observed during all
relapses. Using T2-weighted imaging, response to cortico-
steroid therapy was observed during all relapses except 2.
At the end of the follow-up period, additional MR
imaging features were noted, including brainstem atro-
phy, spinal cord atrophy, and black hole in the cerebel-
lum (Figure 4J, K, and L). Cystic aspect, leptomenin-
geal or pachymeningeal involvement, microbleeds, or
decrease in the apparent diffusion coefficient was not
observed.
CSF FINDINGS
Twenty-nine CSF samples were obtained from 12 pa-
tients. Twenty six were obtained during relapses, and 3
were obtained between relapses.
In 26 CSF samples obtained during relapses, el-
evated protein level was the most frequent abnormality.
10
6
8
4
2
0
0 50 100 150 200
Time, mo
ED
SS
 S
co
re
Patient 4
Cyclophosphamide (6 cycles)
EDSS score
Pulse corticosteroid therapy
Anti-CD20 (1 cycle)
10
6
8
4
2
0
0 5 10 15 20
Time, mo
ED
SS
 S
co
re
Patient 1
10
6
8
4
2
0
0 5 10 15 20 25 30
Time, mo
ED
SS
 S
co
re
Patient 2
10
6
8
4
2
0
0 5 10 15 20 25
Time, mo
ED
SS
 S
co
re
Patient 3
10
6
8
4
2
0
0 50 100 150 200 250 300 350 400 450
Time, mo
ED
SS
 S
co
re
Patient 5
Figure 2. Clinical course of 5 patients having chronic lymphocytic inflammation with pontine perivascular enhancement responsive to corticosteroids who did not
receive long-term corticosteroid therapy. EDSS indicates Expanded Disability Status Scale.
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Figure 3. Clinical course of 7 patients having chronic lymphocytic inflammation with pontine perivascular enhancement responsive to corticosteroids who
received long-term corticosteroid therapy. EDSS indicates Expanded Disability Status Scale.
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Protein levels were between 0.05 and 0.1 g/dL in 18
samples, greater than 0.1 g/dL in 1 sample, and normal
(0.05 g/dL) in 7 samples (to convert protein level to
grams per liter,multiply by 10.0).White blood cell counts
were greater than 50/µL in 3 samples, between3 and49/µL
in 11 samples, and normal (3/µL) in 12 samples (to con-
vert white blood cell count to109/L,multiply by 0.001).
Intrathecal synthesis of oligoclonal bands (OBs) was ob-
served in 6 of 26 samples during relapses (in patients 3,
4, 5, and 9). The presence of OBs varied during relapses
(observed during relapses 1 and 2 in patient 3, relapse 2
in patient 4, and relapses 9 and 12 in patient 5); they dis-
appeared in later events (relapse 3 in patient 3 and re-
lapses 10 and 11 in patient 5). The CSF T-cell ratio of
CD4 to CD8 was obtained in 4 patients, showing a high
ratio (normal range, 1.6-2.4) in 3 of them (3.4 in pa-
tients 2 and 12 and 5.8 in patient 9).
Three CSF samples obtained between relapses showed
mild elevated protein level (0.07 g/dL) in 1 sample and
mild pleocytosis in 2 samples (5-9/µL, with lymphocyte
predominance). Oligoclonal bands were not observed.
NEUROPATHOLOGICAL
CHARACTERISTICS
Patients 1, 3 through 7, and 9 underwent stereotactic
brain biopsy (6 in the posterior fossa and 1 in the
frontocerebral hemisphere), without adverse effects.
All biopsy specimens revealed parenchymal and peri-
vascular inflammatory infiltrates without demyelin-
ation, granulomatous inflammatory, or necrotizing
vasculitis pattern. These infiltrates were predomi-
nantly composed of T cells (CD3 positive) in 6
patients and of T cells (CD3 positive) and microglia
(CD68 positive) in patient 7. Histological sections
from 5 patients with marked T-lymphocyte infiltration
were also stained for CD4, CD8, and granzyme B and
showed increased CD4 T cells associated with few
CD8 T cells and very little or absent granzyme B
(Figure 5). Some microglia were observed in 6
samples, some B cells (CD20 positive) in 3 samples,
some plasmocytes (CD38 or CD138 positive) in 2
samples, some neutrophils in 2 samples, and reactive
A Patient 4 B Patient 8 C
K
Patient 8
G Patient 8
D Patient 8
E Patient 4 F Patient 4 H Patient 8
I Patient 7 J Patient 5 Patient 4 L Patient 8
Figure 4. Relevant magnetic resonance imaging in 12 patients having chronic lymphocytic inflammation with pontine perivascular enhancement responsive to
corticosteroids using gadolinium-enhanced T1-weighted and T2-weighted imaging. Gadolinium-enhanced T1-weighted images show a homogeneous
gadolinium-enhancing lesion greater than 3 mm (A) and a gadolinium-enhancing pattern as a closed ring (B). Increased T2-weighted signal is confluent (C) and
exceeds the size of the corresponding punctuate gadolinium-enhancing lesions (D). Axial (E) and sagittal (F) gadolinium-enhanced T1-weighted images show
juxtacortical lesions. Gadolinium-enhanced T1-weighted (G) and T2-weighted (H) images show a large confluent spinal cord lesion. Pons swelling (I), brainstem
atrophy ( J), spinal cord atrophy (K), and black hole (L) are shown.
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gliosis (glial fibrillary acid protein positive) in 2
samples. The results of immunohistochemistry for
CD1a were negative. No evidence of -amyloid depos-
its was seen. In 2 of 7 biopsy specimens (from patients
5 and 6), axonal swelling and torpedoes, together with
some focal secondary demyelination, were observed in
the vicinity of inflammatory perivascular lesions; it
was not possible to make conclusions about the other
5 patients.
PROGNOSTIC CRITERIA
Patients 3 through 6 had a severe last EDSS score of 4.5
or higher. Patients 4 and 5 had brainstem and spinal cord
atrophy, and all 4 patients experienced 1 or more severe
relapses (EDSS score, 5). The other 8 patients had a
less severe course. Annualized relapse rates, CSF find-
ings, and brain biopsy results did not differ between the
2 groups of patients.
Immunostaining
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Figure 5. Neuropathological findings in patients 1, 3, 5, 6, and 9, show marked perivascular infiltrates. Infiltrates were predominantly composed of CD4 T cells,
associated with few CD8 T cells and very low or absent granzyme B. Original magnification 100 for patient 3; all others are original magnification 400.
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COMMENT
This study furthers our understanding of CLIPPERS. Dur-
ing amean follow-up period of 5.5 years, 42 relapses were
observed in 12 patients. During relapses, symptoms oc-
curredprogressively during ameandurationof 2.5months.
The mean EDSS score during relapses was 4. All patients
had a relapsing-remitting disease course, with a mean an-
nualized relapse rate of 0.5. Although all relapseswere sen-
sitive to high doses of corticosteroids, two-thirds of re-
lapses left sequelae (mean EDSS score, 1.9). Progressive
clinical worsening was seen during relapses until cortico-
steroid treatment was started. One patient who did not re-
ceive corticosteroid treatment died. No relapses occurred
among 7 patients whose long-term daily dose of cortico-
steroids was 20 mg or higher. Relapse-free periods were
longer when corticosteroid weaning was slower. Second-
aryprogressionwasnotobserved.Whenapatientwith signs
of CLIPPERS fails to respond to corticosteroids, other di-
agnoses shouldbe considered (eg, low-grade glioma7 or pri-
mary central nervous lymphoma11). No secondary pro-
gressionwas seenbetween relapses.ThemedianEDSS score
at the end of the follow-up period was 3.
Several previously undescribed MR imaging features
were seen in someof ourpatients during relapses, includ-
ing pons or middle cerebellar peduncle swelling, closed
ringenhancement, andnormal initialMR imaging.2At the
end of the follow-up period, additional MR imaging fea-
tureswere seen in somepatients, primarily extensive spi-
nal cord involvement, followedbyspinal cordatrophyand
black holes. Pontocerebellar atrophy was also seen, con-
firming recently reportedcasesofCLIPPERS.10 Incontrast
to previous findings, brainstemmass effectwas observed
duringsomerelapses in thepresent study.Therefore,mass
effect is not typical but does not exclude CLIPPERS di-
agnosis.Notably, cavitary aspectswere not foundherein,
in contrast to the study by Duprez and Sindic.3
Oligoclonal bands were present in 4 of 12 patients,
only during relapses. Evolution of OBs is variable; they
can appear or disappear during and following relapses
in the same patient, confirming CSF findings previously
described in 2 isolated cases of CLIPPERS.1,4 The T-cell
ratio of CD4 to CD8 in CSF (not analyzed previously)
was increased in 3 of 4 CSF samples herein.
Brain biopsy specimens in our patients demon-
strated classic T-cell infiltrates. Staining for CD4, CD8,
and granzyme B showed increased CD4 T cells in 5 of 7
samples, similar to findings by Simon and colleagues10
in their recent publication reporting 5 cases of CLIPPERS.
Relapses with an EDSS score of 5 or higher and brain-
stem or spinal cord atrophy seemed to be associated with
severe long-term disability. In contrast, annualized re-
lapse rates of relapses, CSF findings, and brain biopsy re-
sults in our patients were unrelated to final EDSS scores.
Thesedatasuggestthatpulsecorticosteroidtreatmenthas
tobestartedasearlyaspossibleduringarelapsetolimitclini-
cal worsening during the relapse, followed by progressive
tapering. High-dose (20mg once daily) long-term corti-
costeroidtherapyseemstopreventfurtherrelapses.Toavoid
corticosteroid-relatedadverseeffects,otherimmunosuppres-
sive treatmentmay be proposed. In some reported cases of
CLIPPERS,effectiveimmunosuppressivemaintenancetreat-
menttopreventrelapses(aftercompletecorticosteroidwith-
drawal)wasdescribedusingmethotrexate in4patients1,4,6,8
and cyclophosphamide in 1 patient.6 Three of our patients
(2patientswithcyclophosphamideand1patientwithanti-
CD20 treatment) became relapse free after add-on immu-
nosuppressive treatment.However,oneof these(patient4)
experienced a new relapse at 16 months after pulse cyclo-
phosphamide therapy, suggesting that cyclophosphamide
only suspends the symptoms. The efficacy of other immu-
nomodulatoryorimmunosuppressivetherapies(ie,hydroxy-
chloroquinesulfate,mitoxantronehydrochloride, immune
globulinintravenouspentetate,azathioprine,andmycophe-
nolate mofetil1,5,10) has not been proven.
The pathogenesis of CLIPPERS is unknown. Charac-
teristic imaging patterns of punctuate enhancement in-
volving white matter and gray matter, together with peri-
vascular inflammatory infiltrate in brain biopsy specimens,
favor an inflammatory disorderwith a vascular or perivas-
cular tropism. Considering the anatomic arrangement of
small intra-axial veins of the CNS,12 the predominant in-
volvement of brainstemstructuresmight be related to a pri-
mary CNS venous inflammatory disorder. To explain the
particular features of CLIPPERS, Pittock and colleagues1
suggest a specific immune-mediatedprocessdirectedagainst
an epitope localized in the pons. The appearance or dis-
appearanceofOBsduringand following relapses in the same
patient suggests an immuneprocess different from that de-
scribed in multiple sclerosis. Effectors of the inflamma-
tion process seem to be T lymphocytes, with a predomi-
nanceofCD4cells, as seen inCSF samples andbrainbiopsy
specimens in the present study. Further studies are needed
to confirm that prolonged corticosteroid therapy is the op-
timal means to prevent further relapses.
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